Physiological Effect: Neuromuscular Blockade

Drugs with Physiological Effect: Neuromuscular Blockade

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	ZIANA	clindamycin phosphate; tretinoin	GEL;TOPICAL	050802-001	Nov 7, 2006	AB1	RX	Yes	Yes
Organon Llc	XACIATO	clindamycin phosphate	GEL;VAGINAL	215650-001	Dec 7, 2021		RX	Yes	Yes	11,129,896
Organon Llc	XACIATO	clindamycin phosphate	GEL;VAGINAL	215650-001	Dec 7, 2021		RX	Yes	Yes	12,303,563		Y
Organon Llc	XACIATO	clindamycin phosphate	GEL;VAGINAL	215650-001	Dec 7, 2021		RX	Yes	Yes
Organon Llc	XACIATO	clindamycin phosphate	GEL;VAGINAL	215650-001	Dec 7, 2021		RX	Yes	Yes
Bausch	ONEXTON	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050819-002	Nov 24, 2014	AB	RX	Yes	Yes	9,504,704		Y

Neuromuscular Blockade Drugs: Market Dynamics, FDA Exclusivity and Patent Landscape

Last updated: July 31, 2026

Neuromuscular blockade is a mature injectable-drug market dominated by generic small molecules. The principal agents are rocuronium, vecuronium, cisatracurium, atracurium, succinylcholine, pancuronium and mivacurium. Their composition-of-matter patents have expired, and generic competition is established in the United States and major international markets.

The main remaining commercial asset is sugammadex, marketed as Bridion by Merck and licensed to Organon in several markets. Sugammadex is a selective reversal agent for rocuronium- and vecuronium-induced blockade rather than a neuromuscular blocker itself. Its commercial value comes from rapid reversal, operating-room workflow and avoidance of residual paralysis, not from a durable patent monopoly on the older blocking agents.

What drugs produce a neuromuscular blockade?

Neuromuscular-blocking drugs interrupt transmission at the neuromuscular junction and produce skeletal-muscle paralysis. They are used during anesthesia, endotracheal intubation, mechanical ventilation and selected intensive-care procedures.

Depolarizing neuromuscular blockers

Active ingredient	Principal product type	Mechanism	Current market position
Succinylcholine chloride	Injection	Depolarizing nicotinic acetylcholine-receptor agonist	Generic, low-cost, rapid onset
Suxamethonium	International name for succinylcholine	Depolarizing blockade	Generic outside the United States

Succinylcholine remains important for rapid-sequence intubation because of its rapid onset and short duration. Its use is constrained by hyperkalemia, malignant hyperthermia risk, bradyarrhythmia and other contraindications described in FDA labeling.[1]

Nondepolarizing neuromuscular blockers

Active ingredient	Chemical class	Typical clinical role	Reversal options
Rocuronium bromide	Aminosteroid	Routine and emergency intubation	Sugammadex or neostigmine
Vecuronium bromide	Aminosteroid	Maintenance of surgical paralysis	Sugammadex or neostigmine
Pancuronium bromide	Aminosteroid	Longer-duration blockade	Neostigmine
Atracurium besylate	Benzylisoquinolinium	Intermediate-duration blockade	Neostigmine
Cisatracurium besylate	Benzylisoquinolinium	Organ-independent elimination profile	Neostigmine
Mivacurium chloride	Benzylisoquinolinium	Shorter-duration blockade	Neostigmine

Rocuronium is the leading intubating agent in many markets because it combines rapid onset with broad availability. Cisatracurium has a differentiated clinical profile because Hofmann elimination reduces reliance on renal and hepatic clearance. Vecuronium and pancuronium are older aminosteroid agents with extensive generic competition.[2-6]

What patents protect neuromuscular-blocking drugs?

The core composition-of-matter patents for the established neuromuscular blockers have expired. Current patent value is concentrated in formulations, delivery systems, manufacturing processes, reversal agents and use claims.

Historical U.S. patent estate

Drug	Representative originator	Representative patent	Approximate U.S. patent status
Rocuronium	Organon	U.S. Patent No. 4,894,373	Expired
Cisatracurium	Glaxo Wellcome	U.S. Patent No. 5,569,743	Expired
Atracurium	Burroughs Wellcome	Early benzylisoquinolinium compound patents	Expired
Vecuronium	Organon	Early steroidal neuromuscular-blocker patents	Expired
Pancuronium	Organon and predecessors	Early steroidal compound patents	Expired
Succinylcholine	Multiple historical sponsors	Pre-1980 compound and formulation patents	Expired
Sugammadex	Merck	U.S. Patent No. 6,670,340 and related filings	Core term expired; regulatory and jurisdiction-specific rights required separate review

Patent terms for the older agents ended years before the current generic market formed. For patents filed after June 8, 1995, U.S. patent term generally runs 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers and patent-term extension.[7]

The cited rocuronium and cisatracurium patents are historical examples of the original chemical protection. They do not create current U.S. exclusivity for generic versions.

Are there active formulation patents for neuromuscular blockers?

Formulation patent risk is generally low for conventional products supplied as sterile injectable solutions or lyophilized powders. Generic manufacturers have commercialized products using standard excipients, concentrations and vial configurations.

Potentially relevant formulation claims can cover:

• pH-controlled aqueous solutions;
• lyophilized presentations;
• stability during storage;
• low-concentration or premixed bags;
• preservative-free containers;
• prefilled syringes;
• ready-to-use emergency formulations;
• compatibility with infusion systems.

These claims have limited blocking power when a generic can use a non-infringing formulation. The practical risk is greater for a product that depends on a specific stability profile, container-closure system or ready-to-administer presentation than for a conventional vial.

When do neuromuscular-blocking drugs lose exclusivity?

The principal drugs lost exclusivity between the 1980s and 2010s. FDA-approved generic injectables now define the market.

Drug	First commercial era	Current U.S. exclusivity position	Generic entry profile
Succinylcholine	1950s	No meaningful modern patent exclusivity	Multiple generic suppliers
Pancuronium	1970s	Expired	Generic, limited demand
Vecuronium	1980s	Expired	Generic
Atracurium	1980s	Expired	Generic
Mivacurium	1990s	Expired	Generic or limited availability
Rocuronium	1990s	Expired	Broad generic competition
Cisatracurium	1990s	Expired	Generic competition
Sugammadex	2010s U.S. launch	Core patent exclusivity expired; generic approvals established	Originator remains commercially important

Bridion received FDA approval in 2015 for reversal of rocuronium- or vecuronium-induced blockade.[8] FDA approved the first generic sugammadex injection in 2021, and subsequent generic approvals expanded competition.[9]

What is the Orange Book status of neuromuscular-blockade drugs?

The Orange Book lists approved drug products and patent information submitted by sponsors for applicable products. Older neuromuscular blockers generally have no meaningful unexpired composition-of-matter protection in the United States.

Orange Book implications by product

Rocuronium bromide injection

Rocuronium products are generic injectable drugs. FDA-approved labeling identifies rocuronium bromide as a nondepolarizing neuromuscular-blocking agent for intubation and skeletal-muscle relaxation during surgery or mechanical ventilation.[2] A generic applicant typically relies on an abbreviated new drug application and demonstrates pharmaceutical equivalence and bioequivalence.

Cisatracurium besylate injection

Cisatracurium is also a mature generic injectable. FDA labeling emphasizes its use for intubation, surgical relaxation and mechanical ventilation, with Hofmann elimination contributing to its pharmacokinetic profile.[3]

Succinylcholine chloride injection

Succinylcholine has extensive generic availability. Its market is influenced more by clinical contraindications, hospital protocols and supply reliability than by patents.[1]

Sugammadex injection

Sugammadex generated the most significant modern Orange Book and Paragraph IV activity in the category. The product’s commercial claims center on reversal of rocuronium- and vecuronium-induced blockade. Generic applicants challenged listed patents as part of the ANDA process, and FDA-approved generic products are now available.[8-10]

Which companies are challenging neuromuscular-blockade patents?

Generic injectable manufacturers have been the principal challengers to the relevant patent estates. The competitive group has included companies such as Sandoz, Hikma, Fresenius Kabi, Pfizer, Teva, Dr. Reddy’s Laboratories, Gland Pharma, Amneal and other regional suppliers.

For older agents, patent challenges are no longer the central competitive event because the principal patents expired long ago. For sugammadex, ANDA litigation and Paragraph IV certifications were commercially relevant during the transition from branded exclusivity to generic entry.

A Paragraph IV certification states that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic. The first substantially complete Paragraph IV filing can create 180-day exclusivity for a qualifying first applicant under the Hatch-Waxman framework.[11] That exclusivity is separate from the originator’s patent term and can delay later generic approvals.

What patent litigation affects sugammadex and other blockade drugs?

Patent litigation has been concentrated in branded sugammadex rather than in rocuronium, cisatracurium or succinylcholine.

Sugammadex litigation risks

The relevant disputes have generally involved:

• cyclodextrin-based reversal chemistry;
• pharmaceutical compositions;
• methods of reversing aminosteroid neuromuscular blockade;
• dosing and administration;
• patent validity and infringement;
• pediatric or regulatory exclusivity;
• launch timing under settlement agreements.

The core commercial issue was whether generic sugammadex could launch before expiration of the originator’s remaining U.S. patent rights. FDA approval of generic versions materially reduced that risk.[9]

Litigation status for older blockers

Rocuronium and cisatracurium are unlikely to present meaningful current U.S. composition patent litigation risk. Litigation can still arise over:

• manufacturing-process patents;
• formulation patents;
• trade secrets;
• supply contracts;
• ANDA product labeling;
• patent ownership and listing disputes;
• foreign-country rights.

These issues are product-specific and do not restore broad exclusivity to the active ingredient.

How strong is the patent estate for neuromuscular-blockade drugs?

Patent-strength assessment

Asset	Composition patent strength	Formulation risk	Method-of-use risk	Commercial patent strength
Succinylcholine	None in the modern market	Low	Low	Very low
Rocuronium	Expired	Low to moderate	Low	Low
Vecuronium	Expired	Low	Low	Very low
Cisatracurium	Expired	Low to moderate	Low	Low
Atracurium	Expired	Low	Low	Very low
Pancuronium	Expired	Low	Low	Very low
Mivacurium	Expired	Low	Low	Very low
Sugammadex	Core rights expired or eroded by generic entry	Moderate	Moderate historically	Moderate during transition, declining after generic entry

Sugammadex has the strongest modern patent history because it introduced a distinct reversal mechanism and a new cyclodextrin-based active ingredient. Its present commercial defense depends more on brand preference, hospital contracting, supply, clinical evidence and manufacturing scale than on a broad blocking patent.

What manufacturing and intellectual-property barriers affect generic entry?

Manufacturing barriers are more important than patent barriers for most neuromuscular blockers.

Sterile injectable manufacturing

Generic suppliers must manage:

• aseptic processing;
• particulate and endotoxin controls;
• container-closure integrity;
• product sterility;
• extractables and leachables;
• short or variable supply chains;
• drug-shortage risk;
• validated sterilization and filling processes.

Injectable products can face entry delays even after patent expiry because a generic manufacturer must obtain FDA approval and maintain a compliant sterile manufacturing network.

Active pharmaceutical ingredient supply

Rocuronium, cisatracurium, vecuronium and other older agents require specialized active pharmaceutical ingredients. Supplier concentration can produce temporary shortages or price increases, particularly when hospitals use a narrow formulary.

Sugammadex manufacturing

Sugammadex is a complex modified cyclodextrin with a more demanding synthesis and purification profile than many conventional small-molecule injectables. Manufacturing know-how, impurity control and scale-up can create a higher entry barrier than the legal patent estate alone suggests.

What is the FDA regulatory status of neuromuscular blockers?

Neuromuscular blockers are FDA-approved prescription injectable drugs. They are administered in settings capable of airway management, ventilation and monitoring.

FDA-approved labeling covers:

• endotracheal intubation;
• skeletal-muscle relaxation during surgery;
• mechanical ventilation;
• reversal of rocuronium- and vecuronium-induced blockade with sugammadex;
• reversal of nondepolarizing blockade with neostigmine in appropriate circumstances.

Sugammadex is not a biosimilar product. It is a conventional small-molecule drug approved through the NDA and ANDA pathways. Biosimilar competition does not apply to rocuronium, cisatracurium, succinylcholine or sugammadex.

How does sugammadex compare with neostigmine?

Attribute	Sugammadex	Neostigmine
Primary use	Reversal of rocuronium or vecuronium	Reversal of nondepolarizing blockade
Mechanism	Encapsulates aminosteroid blocker molecules	Inhibits acetylcholinesterase
Onset of reversal	Generally rapid and dose-dependent	Dependent on depth of blockade
Anticholinergic coadministration	Usually not required in the same manner	Often paired with glycopyrrolate or atropine
Patent position	Modern patent estate, now facing generics	Long-expired generic product
Cost	Higher acquisition cost	Low acquisition cost
Hospital value driver	Rapid, predictable reversal and workflow	Lower drug cost

Sugammadex expanded the addressable value of rocuronium and vecuronium by making rapid reversal more predictable. Hospitals weigh its higher acquisition cost against operating-room efficiency, reduced residual blockade and patient-management considerations.[8]

What generic entry risks exist for neuromuscular-blockade drugs?

Low-risk products

Succinylcholine, pancuronium, vecuronium and atracurium have low patent-based entry risk. Commercial risk is concentrated in manufacturing, shortages, procurement contracts and limited market size.

Moderate-risk products

Rocuronium and cisatracurium have low legal barriers but can have moderate operational barriers. Suppliers must meet sterile-injectable requirements, maintain supply continuity and compete for hospital contracts.

Higher historical risk

Sugammadex had the highest historical patent and regulatory risk. That risk declined after generic FDA approvals. Current competition is shaped by:

• generic launch timing;
• authorized or branded-generic strategies;
• hospital formulary decisions;
• price erosion;
• manufacturing capacity;
• residual formulation or method claims;
• international patent differences.

How large is the commercial opportunity?

The market is fragmented by molecule and hospital use case. Rocuronium and sugammadex account for the highest commercial value in many markets because they are used together in modern anesthesia protocols. Succinylcholine remains clinically important but has lower pricing. Cisatracurium has a defensible clinical niche but a limited patent-based premium.

Organon reported Bridion net sales of approximately $1.1 billion in 2023, reflecting the product’s scale before and during the expansion of generic competition.[12] The product’s revenue exposure is materially greater than that of most individual generic neuromuscular blockers.

Revenue exposure by product

Product	Revenue exposure	Main erosion driver
Bridion	High historically	Generic sugammadex, contracting and price erosion
Rocuronium	Moderate market volume, low unit price	Multiple generic suppliers
Cisatracurium	Niche to moderate	Generic pricing and hospital substitution
Succinylcholine	High clinical importance, low price	Generic competition and supply conditions
Vecuronium	Low to moderate	Substitution by rocuronium
Atracurium	Niche	Substitution and generic pricing
Pancuronium	Low	Reduced clinical use
Mivacurium	Low	Limited demand and availability

How does the patent landscape vary by geography?

U.S. patent expiry does not establish global freedom to launch. Patent and regulatory positions differ across Europe, Japan, China, India, Canada, Latin America and emerging markets.

United States

The market has extensive generic competition for the established blockers. Sugammadex generic entry has reduced originator exclusivity.

Europe

European national validations, supplementary protection certificates and country-specific litigation can produce different launch dates. European market access also depends on centralized or national regulatory procedures and hospital procurement.

Japan

Japan has distinct approval, pricing and reimbursement procedures. Local patent term adjustments and regulatory requirements can affect launch timing.

China and India

Local manufacturing capacity is important. Patent risk may be lower for older agents, but regulatory approval, local clinical requirements, API controls and procurement systems can determine commercial access.

What generic launch scenarios are most likely?

Scenario 1: Conventional generic price erosion

For rocuronium, cisatracurium and succinylcholine, multiple suppliers compete on price and supply reliability. Gross margins compress, while hospitals retain products with dependable availability.

Scenario 2: Limited supplier market

A small number of qualified sterile-injectable manufacturers can support higher prices during shortages. This is a supply-driven outcome rather than a patent-driven one.

Scenario 3: Sugammadex substitution

Generic sugammadex reduces acquisition cost and may broaden use. The originator can retain share through manufacturing reliability, contracting, clinical familiarity and hospital protocols.

Scenario 4: Formulation differentiation

Ready-to-use syringes, premixed infusion products or improved stability could support premium pricing if protected by enforceable claims and accepted by hospital buyers.

Key Takeaways

• The core patents for rocuronium, cisatracurium, succinylcholine, vecuronium, atracurium, pancuronium and mivacurium have expired.
• The U.S. market is generic and has low composition-of-matter patent risk.
• Sugammadex is the principal modern commercial asset associated with neuromuscular blockade reversal.
• FDA-approved generic sugammadex has reduced the originator’s exclusivity and increased price pressure.
• No biosimilar pathway applies because these products are conventional small-molecule drugs.
• Sterile manufacturing, API supply, shortages and hospital contracting are more important than patents for most current market outcomes.
• Formulation and method-of-use patents can affect individual products but are unlikely to recreate broad molecule-level exclusivity.
• Bridion has the highest historical revenue exposure, while rocuronium has the strongest underlying procedural demand among the blockers.

FAQs About Neuromuscular-Blockade Drug Patents

Is rocuronium still patent protected?

The original U.S. composition-of-matter protection for rocuronium has expired. Current generic entry risk is primarily regulatory, manufacturing and commercial rather than composition-patent based.

Does sugammadex have generic competition?

Yes. FDA-approved generic sugammadex products have entered the U.S. market, reducing the exclusivity available to Bridion.[9]

Are neuromuscular blockers biologics?

No. Succinylcholine, rocuronium, vecuronium, cisatracurium, atracurium, pancuronium, mivacurium and sugammadex are conventional small-molecule drugs.

Which neuromuscular blocker has the strongest commercial position?

Rocuronium has strong procedural demand, while sugammadex has historically generated the greatest branded revenue. Their commercial positions are linked because sugammadex reverses rocuronium and vecuronium.

Can a new formulation of rocuronium obtain patent protection?

Yes, a novel formulation, container system, stability profile or delivery method may qualify for patent protection if it satisfies patentability requirements. Such protection would normally be narrower than an expired composition patent.

References

1. U.S. Food and Drug Administration. (2023). Succinylcholine chloride injection prescribing information.

2. U.S. Food and Drug Administration. (2023). Rocuronium bromide injection prescribing information.

3. U.S. Food and Drug Administration. (2023). Cisatracurium besylate injection prescribing information.

4. U.S. Food and Drug Administration. (2023). Vecuronium bromide for injection prescribing information.

5. U.S. Food and Drug Administration. (2023). Atracurium besylate injection prescribing information.

6. U.S. Food and Drug Administration. (2023). Mivacurium chloride injection prescribing information.

7. United States Code. (2024). 35 U.S.C. § 154: Contents and term of patent; provisional rights.

8. U.S. Food and Drug Administration. (2015). Bridion (sugammadex) prescribing information.

9. U.S. Food and Drug Administration. (2021). FDA approves first generic of Bridion to reverse effects of certain muscle relaxants used during surgery.

10. U.S. Patent and Trademark Office. (2024). Orange Book patent and exclusivity data.

11. U.S. Food and Drug Administration. (2024). Guidance for industry: 180-day exclusivity for generic drug products.

12. Organon & Co. (2024). 2023 annual report.